~ Buy the CIBINQO (abrocitinib) Drug Profile, 2024 PDF Report in the Report Store ~

Drug Price Trends for CIBINQO

Average Pharmacy Cost for CIBINQO

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
CIBINQO 100 MG TABLET	00069-0335-30	189.33034	EACH	2025-01-01
CIBINQO 100 MG TABLET	00069-0335-30	180.31461	EACH	2024-12-18
CIBINQO 100 MG TABLET	00069-0335-30	180.09547	EACH	2024-11-20

Market Analysis and Price Projections for CIBINQO

Introduction to CIBINQO

CIBINQO, also known as abrocitinib, is a Janus Kinase 1 (JAK1) inhibitor developed by Pfizer for the treatment of moderate to severe atopic dermatitis (AD) in adults who have not responded adequately to other treatments, including biologics. Here’s a comprehensive analysis of its market position and price projections.

FDA Approval and Clinical Trials

CIBINQO received FDA approval in January 2022, following a series of clinical trials that involved over 1,600 patients. These trials demonstrated significant improvements in disease outcomes compared to placebo, particularly in reducing symptoms and improving quality of life for patients with refractory moderate to severe AD[1][4].

Market Position

CIBINQO enters a market dominated by Sanofi and Regeneron's Dupixent, which has annual sales of around 6 billion euros as of 2021. However, CIBINQO is positioned as a secondary treatment option for patients who do not respond adequately to Dupixent or other systemic treatments. Analysts from ODDO BHF note that CIBINQO's label is "very favorable" for Sanofi, as it suggests CIBINQO will be prescribed only after Dupixent has failed to provide adequate treatment[1].

Pricing and Cost

The pricing of CIBINQO is a critical factor in its market viability. Here are some key points:

• Cost per Patient: The annual cost of treatment with CIBINQO is estimated to be between $17,765 and $19,882 per patient in Canada, highlighting the drug's significant expense[3].
• Dose-Specific Pricing: In the U.S., the cost for a 30-tablet supply of CIBINQO ranges from approximately $5,871.88 for the 50 mg, 100 mg, and 200 mg doses. This translates to a per-unit cost of around $195.73 per tablet[2].
• Cost-Effectiveness: The Canadian Agency for Drugs and Technologies in Health (CADTH) has noted that CIBINQO is not cost-effective at current prices, requiring a price reduction of at least 52% to 56% to meet a $50,000 per Quality-Adjusted Life Year (QALY) threshold[3].

Sales Projections

Pfizer has set ambitious sales targets for CIBINQO, anticipating peak sales of $3 billion. This figure is based on capturing an 8% market share of the systemic atopic dermatitis market. Given the drug's positioning as a secondary treatment option, achieving this target will depend on its adoption by healthcare providers and patient response to the treatment[1].

Competitive Landscape

CIBINQO faces stiff competition from established treatments like Dupixent. However, its unique mechanism of action as a JAK1 inhibitor and its oral administration could offer advantages in patient compliance and convenience compared to injectable biologics.

Mechanism of Action and Patient Compliance

CIBINQO's mechanism as a JAK1 inhibitor provides a targeted approach to reducing inflammation in AD patients. This oral medication can be more appealing to patients who prefer or require an oral treatment option over injectable biologics. The convenience and ease of administration could drive patient preference and adherence[5].

Generic Entry and Patent Protection

CIBINQO is protected by three U.S. patents and two FDA regulatory exclusivities. The earliest estimated date for generic entry is based on patent analysis, but various factors such as new patent filings, patent extensions, or early generic licensing could influence the actual generic entry date. This protection ensures Pfizer's exclusivity for a significant period, allowing the company to recoup its investment and maximize revenue before generic competition arises[5].

Reimbursement and Access

The reimbursement landscape for CIBINQO is crucial for its market success. In Canada, CADTH recommends reimbursement for CIBINQO under specific conditions, including documented refractory disease or intolerance to other systemic treatments. Similar reimbursement criteria are likely to be applied in other countries, influencing the drug's accessibility and adoption[3].

Key Takeaways

• FDA Approval: CIBINQO received FDA approval in January 2022 for treating moderate to severe atopic dermatitis.
• Pricing: The drug is priced around $5,871.88 for a 30-tablet supply, with annual costs estimated between $17,765 and $19,882 per patient.
• Sales Projections: Pfizer aims for peak sales of $3 billion, targeting an 8% market share.
• Competitive Landscape: CIBINQO competes with Dupixent but is positioned as a secondary treatment option.
• Generic Entry: Protected by patents and regulatory exclusivities, with the earliest generic entry estimated based on patent analysis.
• Reimbursement: Subject to specific reimbursement conditions to ensure cost-effectiveness and patient access.

FAQs

Q1: What is CIBINQO used for? CIBINQO (abrocitinib) is used to treat moderate to severe atopic dermatitis in adults who have not responded adequately to other treatments, including biologics.

Q2: How much does CIBINQO cost? The cost for a 30-tablet supply of CIBINQO is approximately $5,871.88, with annual costs estimated between $17,765 and $19,882 per patient.

Q3: What are the peak sales projections for CIBINQO? Pfizer projects peak sales of $3 billion for CIBINQO, based on capturing an 8% market share of the systemic atopic dermatitis market.

Q4: How does CIBINQO compare to Dupixent? CIBINQO is positioned as a secondary treatment option for patients who do not respond adequately to Dupixent or other systemic treatments. It offers an oral administration option, which could be more convenient for some patients.

Q5: When can we expect generic versions of CIBINQO? The earliest estimated date for generic entry is based on patent analysis, but various factors could influence the actual generic entry date, potentially allowing generics to enter earlier or later than predicted.

Sources

1. FiercePharma: "Pfizer's next blockbuster Cibinqo snags FDA approval to challenge Sanofi and Regeneron's Dupixent"[1]
2. Drugs.com: "Cibinqo Prices, Coupons, Copay Cards & Patient Assistance"[2]
3. CADTH: "Abrocitinib (Cibinqo) - Canada's Drug Agency"[3]
4. FDA: "Drug Trials Snapshot: CIBINQO"[4]
5. DrugPatentWatch: "CIBINQO Drug Patent Profile"[5]